Eikonoklastes Closes Oversubscribed Series A Financing, Helping To Advance Immunotherapies Toward Clinical Trial Stage
Eikonoklastes Closes Oversubscribed Series A Financing, Helping To Advance Immunotherapies Toward Clinical Trial Stage
06/28/21, 1:38 PM
Location
cincinnatiRound Type
series a
Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company, today announced the closing of a Series A financing round, less than a year after the company emerged from stealth with its seed financing.
Company Info
Location
cincinnati, ohio, united states
Additional Info
Eikonoklastes Therapeutics is advancing a new generation of tissue factor (TF) immunotherapies for the treatment of Triple Negative Breast Cancer and a broad range of other diseases with high morbidity and high unmet clinical needs. Eikonoklastes Therapeutics was founded and is led by a management team with longstanding experience of successful drug development. Working with The Ohio State University Corporate Engagement Office and seed investor CincyTech, the company was formed to advance technology discovered and engineered in the lab of Dr. Zhiwei Hu, MD, PhD, and licensed from the Ohio State Innovation Foundation. These novel and proprietary molecules are the third generation of technology that Dr. Hu initially designed while at Yale University.
More at: www.eikonoklastes.com.